Aditxt (Aditxt) Scaled Net Operating Assets : 0.40 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Aditxt Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aditxt's operating assets for the quarter that ended in Mar. 2024 was $27.89 Mil. Aditxt's operating liabilities for the quarter that ended in Mar. 2024 was $10.11 Mil. Aditxt's Total Assets for the quarter that ended in Dec. 2023 was $44.58 Mil. Therefore, Aditxt's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.40.

Aditxt Scaled Net Operating Assets Historical Data

The historical data trend for Aditxt's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aditxt Scaled Net Operating Assets Chart

Aditxt Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-23.19

18.94

0.54

0.35

3.18

Aditxt Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.36	0.19	0.06	4.15	0.40

Competitive Comparison of Aditxt's Scaled Net Operating Assets

For the Biotechnology subindustry, Aditxt's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aditxt's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aditxt's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Aditxt's Scaled Net Operating Assets falls into.

Aditxt Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aditxt's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(44.481	-	10.314)	/	10.735
=	3.18

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	44.578	-	0.097
=	44.481

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	28.532	-	1.042	-	17.176
=	10.314

Aditxt's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(27.887	-	10.108)	/	44.578
=	0.40

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	27.976	-	0.089
=	27.887

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	18.194	-	0.892	-	7.194
=	10.108

Aditxt Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Aditxt's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aditxt (Aditxt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219

Website

https://www.aditxt.com

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.

Executives

Charles Athle Nelson	director	11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp	10 percent owner	787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes	officer: Chief Legal Officer and GC	737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung	director	1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley	officer: PRINCIPAL ACCOUNTING OFFICER	2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge	director	C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna	officer: CHIEF OPERATING OFFICER	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne	officer: CHIEF FINANCIAL OFFICER	BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony	director	LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady	director	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna	director, officer: CHIEF EXECUTIVE OFFICER	871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang	director, officer: CHIEF INNOVATION OFFICER	11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354